Se rendre au contenu

 

Induced Pluripotent Stem Cells (iPSCs) – Roles in Regenerative Therapies, Disease Modelling and Pharmaceutical Screening

Pluripotent stem cells (PSCs) are a unique class of cells capable of self-renewal and differentiation into virtually all cell types of the human body. This property makes them a cornerstone of developmental biology and regenerative medicine research. PSCs include two major types: embryonic stem cells (ESCs), derived from the inner cell mass of blastocysts, and induced pluripotent stem cells (iPSCs), which are generated by reprogramming somatic cells back to a pluripotent state.

What are Induced Pluripotent Stem Cells (iPSCs)

Induced pluripotent stem cells (iPSCs) are adult cells such as fibroblasts or blood cells that have been genetically reprogrammed to an embryonic-like pluripotent state. This reprogramming is typically achieved by introducing specific transcription factors, often referred to as the Yamanaka factors: OCT4, SOX2, KLF4, and c-MYC. These cells acquire the ability to self-renew indefinitely and differentiate into cells of all three germ layers (ectoderm, mesoderm, endoderm), mirroring the capabilities of ESCs without the ethical concerns associated with embryonic tissues.

Generation of iPSCs



The process of generating iPSCs involves several critical steps:

Cell Isolation: Somatic cells, such as skin fibroblasts, blood cells, or urine-derived epithelial cells, are collected from the donor.

Reprogramming: Cells are transduced with transcription factors (OCT4, SOX2, KLF4, c-MYC) using viral or non-viral vectors.

Selection and Expansion: Reprogrammed cells are cultured under conditions that promote pluripotency.

Characterization: iPSCs are verified for pluripotency markers (e.g., NANOG, TRA-1-60) and their ability to differentiate into cell types from all three germ layers.

Advances in non-integrating methods such as mRNA transfection, episomal vectors, or Sendai virus delivery have improved safety by minimizing genetic alterations, making iPSCs suitable for clinical applications.

 Roles of iPSCs in Regenerative Therapies

Cell Replacement Therapy
  • Generation of cardiomyocytes for heart disease, insulin-producing β-cells for diabetes, or dopaminergic neurons for Parkinson’s disease.
  • Patient-specific iPSCs reduce the risk of immune rejection.

 

Tissue Engineering
  • iPSCs can be combined with biomaterials to produce functional tissue constructs for organ repair.
  • Examples include engineered skin, liver organoids, and retinal tissue.
Personalized Medicine
  • iPSC-derived cells reflect the genetic background of the patient, allowing tailored therapeutic interventions and autologous cell therapy.

iPSCs in Disease Modelling

Genetic Diseases

iPSCs derived from patients with cystic fibrosis, muscular dystrophy, or inherited cardiomyopathies can be differentiated into disease-relevant cell types for studying pathology.

Neurodegenerative Disorders

Patient-derived iPSCs can generate neurons to model Parkinson’s, Alzheimer’s, or Huntington’s disease, providing insights into disease progression and mechanisms.

Cancer Research

iPSCs help model tumorigenesis, identify cancer-driving mutations, and test targeted therapies on genetically matched cell lines.

 

iPSCs in Pharmaceutical Screening and Therapeutic  Discovery

  

iPSCs are transforming drug discovery by enabling high-throughput screening in human-relevant cell types:

1

 Toxicity Testing

iPSC-derived hepatocytes, cardiomyocytes, and neurons are used to assess drug-induced liver injury, cardiotoxicity, or neurotoxicity, reducing reliance on animal models.

2

 Efficacy Testing

Drugs can be tested on patient-specific iPSC-derived cells to evaluate therapeutic responses and predict treatment outcomes.

3

High-Throughput Screening Platforms

Large-scale iPSC-derived cell assays allow the identification of novel compounds, repurposing of existing drugs, and personalized therapeutic strategies.

Advantages for Therapeutic Screening

  • Human-specific cell types
  • Genetic diversity reflecting patient populations
  • Reduction of animal testing and better prediction of clinical outcomes